Stocks · News reference

Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target

Sep 24, 2026, 12:40 PMBenzinga Newsdesk

Goldman Sachs analyst Andrea Newkirk reinstates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and announces $704 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 6, 2026, 12:14 PMBenzinga Newsdesk
Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced the publication of a
MDGL
BenzingaSep 23, 2026, 3:04 PMBenzinga Newsdesk
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725
Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy rating and announces Price Target of $725.
MDGL
BenzingaAug 17, 2026, 5:12 PMErica Kollmann
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
AAMI AEM BHC FOLD GOOGL